MA50145A - Composés inhibiteurs de vmat2 et compositions de ceux-ci - Google Patents

Composés inhibiteurs de vmat2 et compositions de ceux-ci

Info

Publication number
MA50145A
MA50145A MA050145A MA50145A MA50145A MA 50145 A MA50145 A MA 50145A MA 050145 A MA050145 A MA 050145A MA 50145 A MA50145 A MA 50145A MA 50145 A MA50145 A MA 50145A
Authority
MA
Morocco
Prior art keywords
compositions
inhibitor compounds
vmat2 inhibitor
vmat2
compounds
Prior art date
Application number
MA050145A
Other languages
English (en)
French (fr)
Inventor
Shawn Branum
Jeffrey C Culhane
Nicole Harriott
Donald Hettinger
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MA50145A publication Critical patent/MA50145A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA050145A 2017-04-19 2018-04-17 Composés inhibiteurs de vmat2 et compositions de ceux-ci MA50145A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US201862652837P 2018-04-04 2018-04-04

Publications (1)

Publication Number Publication Date
MA50145A true MA50145A (fr) 2020-07-29

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050145A MA50145A (fr) 2017-04-19 2018-04-17 Composés inhibiteurs de vmat2 et compositions de ceux-ci

Country Status (17)

Country Link
US (1) US11040970B2 (enExample)
EP (1) EP3612532B1 (enExample)
JP (1) JP7170662B2 (enExample)
KR (1) KR20190140968A (enExample)
CN (1) CN110770236B (enExample)
AU (1) AU2018254429A1 (enExample)
BR (1) BR112019021853A2 (enExample)
CA (1) CA3060251A1 (enExample)
CL (1) CL2019002919A1 (enExample)
CO (1) CO2019011604A2 (enExample)
ES (1) ES2971230T3 (enExample)
JO (1) JOP20190239A1 (enExample)
MA (1) MA50145A (enExample)
MX (1) MX2019012336A (enExample)
PE (1) PE20191784A1 (enExample)
TW (1) TW201841913A (enExample)
WO (1) WO2018195121A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY203491A (en) 2017-01-27 2024-06-30 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
PL3684333T3 (pl) 2017-09-21 2025-06-23 Neurocrine Biosciences, Inc. Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane
KR20250110361A (ko) 2017-10-10 2025-07-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020013004A (es) * 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
MX2021001017A (es) 2018-08-15 2021-04-19 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2).
TW202033521A (zh) * 2018-10-24 2020-09-16 美商紐羅克里生物科學有限公司 製備囊泡單胺轉運蛋白2(vmat2)抑制劑之方法
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
RS67052B1 (sr) 2021-03-22 2025-08-29 Neurocrine Biosciences Inc Vmat2 inhibitori i postupci primene
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
US20250064990A1 (en) 2021-08-20 2025-02-27 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
ES2327740T3 (es) 2003-06-20 2009-11-03 F. Hoffmann-La Roche Ag Hexahidropiridoisoquinolinas como inhibidoras de la dpp-iv.
JP2008509925A (ja) * 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
BRPI0718247B1 (pt) 2006-11-08 2021-09-21 Neurocrine Biosciences, Inc. Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2009126305A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
LT3061760T (lt) 2008-09-18 2018-02-26 Auspex Pharmaceuticals, Inc. Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai
US8772301B2 (en) * 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2014043866A1 (zh) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
WO2016127133A1 (en) 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
KR102696516B1 (ko) 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체

Also Published As

Publication number Publication date
EP3612532C0 (en) 2023-12-13
JP2020517607A (ja) 2020-06-18
EP3612532B1 (en) 2023-12-13
US11040970B2 (en) 2021-06-22
CL2019002919A1 (es) 2020-01-17
WO2018195121A1 (en) 2018-10-25
CN110770236A (zh) 2020-02-07
MX2019012336A (es) 2020-07-14
BR112019021853A2 (pt) 2020-05-26
KR20190140968A (ko) 2019-12-20
ES2971230T3 (es) 2024-06-04
US20200131173A1 (en) 2020-04-30
AU2018254429A1 (en) 2019-11-07
JP7170662B2 (ja) 2022-11-14
TW201841913A (zh) 2018-12-01
EP3612532A1 (en) 2020-02-26
PE20191784A1 (es) 2019-12-24
CA3060251A1 (en) 2018-10-25
CO2019011604A2 (es) 2019-10-31
CN110770236B (zh) 2023-03-24
JOP20190239A1 (ar) 2019-10-09

Similar Documents

Publication Publication Date Title
MA50145A (fr) Composés inhibiteurs de vmat2 et compositions de ceux-ci
EP3897522A4 (en) MICROCAPSULE COMPOSITION
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
EP3481391A4 (en) Therapeutic inhibitory compounds
SI3468966T1 (sl) Zaviralci interakcije menin-MLL
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
MA52896A (fr) Composés inhibiteurs de vmat2, compositions et méthodes associées
EP3349753A4 (en) FUNGICIDE COMPOUNDS AND METHOD OF PREPARING THEREOF
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
EP3317241A4 (en) THERAPEUTIC INHIBITING COMPOUNDS
DK3143026T3 (da) Forbindelser og sammensætninger til induktion af chondrogenese
PT3820712T (pt) Proteção anticontrafação de artigos
EP3842425A4 (en) NOVEL QUINOLINE DERIVATIVE INHIBITORS
MA54143A (fr) Compositions et méthodes
PT3240767T (pt) Composições microencapsuladas de inibidor da nitrificação
EP3556758A4 (en) CDK4 / 6-INHIBITOR
EP3810118A4 (en) Formulations of tegavivint and related compounds
PL4073164T3 (pl) Związki trójamidowe i kompozycje je zawierające
EP3310794A4 (en) Synthesis and Application of Microbial Compounds
IL264445A (en) Compounds and compositions and uses thereof
DK3678644T3 (da) Formuleringer af copanlisib
MA49766A (fr) Benzothiazoles et composés connexes